India Pharma Outlook Team | Wednesday, 28 October 2026
Autoimmune cell therapy development has faced a setback after Artiva Biotherapeutics discontinued its lead candidate, AlloNK, following two patient deaths and concerns about the durability of clinical responses.
The company said one fatal neurological event was assessed as likely related to fludarabine-associated neurotoxicity, while the second death was assessed by the investigator as unrelated to AlloNK or other treatment components, with the cause undetermined.
Artiva will also cut about 94 percent of its workforce and review strategic alternatives.
The decision highlights how safety, sustained benefit and trial feasibility can shape the future of investigational cell therapies for autoimmune disease treatment.
Artiva announced on October 27, 2026, that it would discontinue AlloNK (AB-101), its investigational, donor-derived natural killer (NK) cell therapy, and abandon a planned Phase III trial.
The treatment was being evaluated in combination with rituximab for rheumatoid arthritis and other B-cell-driven autoimmune diseases.
The company cited two serious safety events, insufficient clinical response durability during longer-term follow-up, potential enrolment delays and the overall development and commercial outlook.
Although earlier findings showed deep B-cell depletion and clinical activity, the subsequent follow-up did not demonstrate the sustained benefit Artiva considered necessary to justify continued investment.
This distinction is important when assessing autoimmune cell therapy programs. Evidence of biological activity does not automatically establish lasting clinical improvement or a favourable risk-benefit profile.
The company also plans to reduce its workforce by approximately 94 percent while evaluating strategic alternatives, including a merger, asset sale, licensing arrangement or potential liquidation.
Also Read: How Biologics and Complex Therapies Are Reshaping CDMO Strategy
One of the two fatal events involved leukoencephalopathy, a neurological condition, in a participant in Artiva's Phase II (a) study.
The investigator and an independent safety review assessed the event as likely related to fludarabine-associated neurotoxicity. The treatment regimen included fludarabine and cyclophosphamide for lymphodepletion before cell therapy.
Lymphodepletion reduces certain immune cells before some cellular treatments are administered.
However, the conditioning regimen introduces its own safety considerations, making it important to distinguish the risks associated with preparatory drugs from those associated with the investigational cell product.
The second participant experienced sudden death approximately two months after starting treatment. The investigator assessed that event as unrelated to AlloNK or any other component of the treatment regimen, and the cause remains undetermined.
Fludarabine toxicity is relevant beyond this individual program because fludarabine-containing lymphodepletion regimens are used in cell therapy development.
Such information could help researchers better understand treatment-associated risks, although the findings will need to be assessed in their specific clinical context.
The AlloNK decision also highlights a central challenge in autoimmune cell therapy: translating an initial biological response into sustained improvements for patients.
Autoimmune conditions such as rheumatoid arthritis can require long-term disease management, making the duration of treatment benefit an important consideration.
Artiva reported that updated results continued to show deep B-cell depletion and clinical activity consistent with previously disclosed findings. However, longer-term observations did not meet the company's threshold for continued development.
AlloNK is an example of allogeneic cell therapy, which uses cells obtained from a donor rather than manufactured from the individual patient.
This approach may offer manufacturing and logistical advantages, but its clinical value still depends on demonstrating an acceptable safety profile and sufficiently durable responses.
For drug development pipelines, the outcome reinforces the importance of evaluating the complete evidence package before advancing a candidate into pivotal trials.
.jpg)
